Filing summary
Entity and period: The supplied filing identifies the registrant as NanoAntibiotics, Inc., not BioVie Inc. It is a Form 10-Q for the quarter ended December 31, 2014, covering the three and six months then ended; the balance sheet compares December 31, 2014 with June 30, 2014. This conflicts with the request metadata and should be verified.
Business context
NanoAntibiotics describes itself as an early-stage biotechnology company developing antibiotic candidates for drug-resistant bacterial infections. It had no products for sale or revenue. Its candidates had been tested only in cell-based, in-vitro assays—not in animals—and the company was seeking university nanotechnology licenses to advance development.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2014 | Six months ended Dec. 31, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $70,591 | $129,481 | $47,282 and $100,865, respectively |
| Net loss | $70,485 | $129,261 | $47,126 and $100,619, respectively |
| Net loss per share | $(0.00) | $(0.00) | $(0.00) in both comparable periods |
- Six-month operating cash use was $44,798, compared with $98,869 in the prior-year period. Cash declined from $332,864 at June 30, 2014 to $288,066 at December 31, 2014.
- At December 31, current assets were $293,066 and current liabilities were $247,157, including $242,212 of accrued payroll and $4,945 of accounts payable. The company reported no debt on the balance sheet.
- Stockholders’ equity was $45,909; accumulated deficit was $468,667. Common shares outstanding were 87,210,000. Five million $0.50 warrants remained outstanding and exercisable through 2018.
- No gross margin was generated because there were no sales. The filing reports no interest expense and $220 of interest income for the six-month period.
Changes, outlook, and risks
- Six-month net loss increased by $28,642 year over year, while operating expenses increased by $28,616. Professional fees and selling, general and administrative expenses were recorded in 2014 but not in the comparable 2013 period; reported payroll expense also increased. Research and development expense declined year over year.
- Management estimated next-12-month spending of $575,000 for research and development, $100,000 for corporate overhead, $100,000 for licensing and capital costs, and $180,000 for officers and staffing. It said approximately $600,000 of additional net financing was needed; financing was not committed.
- The filing says existing cash was expected to meet operating and capital needs only until June 30, 2015, and also states funds were insufficient for planned activity over the next 12 months. Management warned that inability to raise funds could force reduced or halted development, licensing or sale of assets, a business combination, or cessation of operations. The filing explicitly raises substantial doubt about the company’s ability to continue as a going concern.
- Development, licensing, regulatory approval, financing, and commercialization are uncertain; management cautioned that budgets and timelines could change. The company reported a five-year office lease beginning January 2014, with monthly payments of $357 and total stated payments of $21,420.
- Management concluded disclosure controls and procedures were not effective as of December 31, 2014. It reported no material change in internal control during the quarter. No material legal proceedings or off-balance-sheet arrangements were reported.
Important facts to verify
- Confirm that this NanoAntibiotics filing, rather than a BioVie filing, is the intended source and that the requested period is the quarter ended December 31, 2014.
- Reconcile research and development expense: the statements show $0 for the December 2014 quarter and $3,400 for the six months, while the notes give conflicting prior-year quarterly figures ($28,750 versus $19,150 in the statements).
- Verify the funding estimate and runway assumptions, including the stated approximately $600,000 financing need and the detailed planned spending budget.
- Assess the going-concern warning, lack of committed financing, development stage of the candidates, and potential dilution from outstanding warrants.